Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Prader-Willi Syndrome
NCT02311673Phase 2Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Mar 2015
- Primary completion
- Oct 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of setmelanotide in Prader-Willi syndrome (PWS) (4 arms), sponsored by Rhythm Pharmaceuticals. Primary endpoints: Number of Participants Who Experienced a Treatment-Emergent Adverse Event - Period 2, Number of Participants Who Experienced a Treatment-Emergent Adverse Event - Period 3 and 5 more. Started Mar 2015; status: completed.
02
Drugs
setmelanotide
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT02311673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02311673.